LSV Asset Management Purchases 10,787 Shares of Halozyme Therapeutics, Inc. $HALO

LSV Asset Management boosted its holdings in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 0.9% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,266,027 shares of the biopharmaceutical company’s stock after acquiring an additional 10,787 shares during the period. LSV Asset Management owned 1.08% of Halozyme Therapeutics worth $92,850,000 at the end of the most recent reporting period.

Several other hedge funds have also added to or reduced their stakes in the stock. DLD Asset Management LP bought a new position in Halozyme Therapeutics in the 2nd quarter worth about $650,250,000. Arrowstreet Capital Limited Partnership raised its holdings in Halozyme Therapeutics by 127.8% in the second quarter. Arrowstreet Capital Limited Partnership now owns 2,541,181 shares of the biopharmaceutical company’s stock worth $132,192,000 after buying an additional 1,425,674 shares during the last quarter. Federated Hermes Inc. lifted its stake in shares of Halozyme Therapeutics by 294.1% in the third quarter. Federated Hermes Inc. now owns 1,450,704 shares of the biopharmaceutical company’s stock worth $106,395,000 after buying an additional 1,082,638 shares in the last quarter. Royal London Asset Management Ltd. grew its holdings in shares of Halozyme Therapeutics by 122.3% during the second quarter. Royal London Asset Management Ltd. now owns 1,101,912 shares of the biopharmaceutical company’s stock valued at $57,321,000 after buying an additional 606,236 shares during the last quarter. Finally, Qube Research & Technologies Ltd purchased a new stake in shares of Halozyme Therapeutics during the second quarter valued at approximately $51,295,000. 97.79% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

HALO has been the subject of a number of recent analyst reports. Wall Street Zen upgraded shares of Halozyme Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Saturday, January 31st. Citigroup reissued a “market outperform” rating on shares of Halozyme Therapeutics in a report on Tuesday, November 4th. HC Wainwright reaffirmed a “buy” rating on shares of Halozyme Therapeutics in a report on Thursday, January 29th. Citizens Jmp increased their price objective on Halozyme Therapeutics from $91.00 to $92.00 and gave the company a “market outperform” rating in a research report on Tuesday, November 4th. Finally, The Goldman Sachs Group reiterated a “sell” rating and issued a $56.00 price objective on shares of Halozyme Therapeutics in a report on Thursday, December 4th. Eight investment analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $78.80.

Insider Transactions at Halozyme Therapeutics

In other Halozyme Therapeutics news, CEO Helen Torley sold 10,000 shares of the business’s stock in a transaction dated Thursday, February 5th. The stock was sold at an average price of $78.64, for a total transaction of $786,400.00. Following the completion of the sale, the chief executive officer directly owned 708,719 shares in the company, valued at $55,733,662.16. The trade was a 1.39% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Bernadette Connaughton sold 2,000 shares of the stock in a transaction that occurred on Monday, January 5th. The stock was sold at an average price of $70.25, for a total transaction of $140,500.00. Following the completion of the transaction, the director owned 40,123 shares in the company, valued at $2,818,640.75. This trade represents a 4.75% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders have sold 49,398 shares of company stock valued at $3,650,592. Corporate insiders own 2.40% of the company’s stock.

Halozyme Therapeutics Price Performance

NASDAQ HALO opened at $76.92 on Friday. The business’s fifty day moving average price is $70.53 and its 200-day moving average price is $69.67. The stock has a market capitalization of $9.05 billion, a price-to-earnings ratio of 16.19, a PEG ratio of 0.33 and a beta of 0.97. The company has a debt-to-equity ratio of 1.59, a current ratio of 1.59 and a quick ratio of 1.37. Halozyme Therapeutics, Inc. has a 1-year low of $47.50 and a 1-year high of $82.22.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.